Development of chronic hepatitis B virus infection in hepatitis B surface antigen negative HIV/HBV co-infected adults: A rare opportunistic illness

Journal of Medical Virology

Volumn 83, Issue 9, 2011, Pages 1537-1543

  Landrum, Michael L ^a,b   Roediger, Mollie P ^a,c   Fieberg, Ann M ^a,c   Weintrob, Amy C ^a,d   Okulicz, Jason F ^b   Crum Cianflone, Nancy F ^a,e   Ganesan, Anuradha ^a,d   Lalani, Tahaniyat ^a,f   Macalino, Grace E ^a   Chun, Helen M ^e  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

Author keywords

CD4 cell count; Chronic hepatitis b virus; Hepatitis b virus; Human immunodeficiency virus; Opportunistic illness

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OPPORTUNISTIC INFECTION; SEROLOGY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COINFECTION; DNA, VIRAL; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE; TIME FACTORS;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79960116623     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22155     Document Type: Article

References (16)

1. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. 1999. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28: 1032-1035.
2. Bodsworth NJ, Cooper DA, Donovan B. 1991. The influence of human immunodeficiency virus type 1 infection on the development of hepatitis B virus carrier state. J Infect Dis 163: 1138-1140.
3. Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, Tamminga CL, Stephan KT, Aronson NE, Fraser SL, Wallace MR, Wegner SA, Mascola JR, McCutchan FE. 2003. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 17: 2521-2527.
4. Centers for Disease Control and Prevention. 2009. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 58: 1-94.
5. Chun HM, Fieberg AM, Hullsiek KH, Lifson AR, Crum-Cianflone NF, Weintrob AC, Ganesan A, Barthel RV, Bradley WP, Agan BK, Landrum ML. 2010. The epidemiology of hepatitis B virus infection in a U.S. cohort of HIV-infected individuals during the last 20 years. Clin Infect Dis 50: 426-436.
6. Cohen Stuart JWT, Velema M, Schuurman R, Boucher CAB, Hoepelman AIM. 2009. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 81: 441-445.
7. French AL, Lin MY, Evans CT, Benning L, Glesby MJ, Young MA, Operskalski EA, Augenbraun M, Peters M. 2009. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. Clin Infect Dis 49: 148-154.
8. Landrum ML, Fieberg AM, Chun HM, Crum-Cianflone NF, Marconi VC, Weintrob AC, Ganesan A, Barthel RV, Wortmann G, Agan BK. 2010a. The effect of human immunodeficiency virus on hepatits B virus serological status in co-infected adults. PLoS ONE 5: e8687.
9. Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, O'Connell RJ, Fieberg A, Chun HM, Marconi VC, Dolan MJ, Agan BK. 2010b. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 24: 545-555.
10. Miailhes P, Trabaud M-A, Pradat P, Lebouche B, Chevallier M, Chevallier P, Zoulim F, Trepo C. 2007. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: Relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 45: 624-632.
11. Morsica G, Ancarani F, Bagaglio S, Maracci M, Cicconi P, Cozzi Lepri A, Antonucci G, Bruno R, Santantonio T, Tacconi L, Baldelli F, Piscop R, Santoro D, Lazzarin A, D'Arminio Monforte A. 2009. Occult hepatitis B virus infection in a cohort of HIV-positive patients: Correlation with hepatitis C virus co-infection, virological and immunological features. Infection 37: 445-449.
12. Nunez M, Ramos B, Diaz-Pollan B, Camino N, Martin-Carbonero L, Barreiro P, Gonzalez-Lahoz J, Soriano V. 2006. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses 22: 842-848.
13. Piroth L, Binquet C, Vergne M, Minello A, Livry C, Bour J, Buisson M, Duong M, Grappin M, Portier H, Chavanet P. 2002. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 36: 681-686.
14. Rouphael NG, Talati NJ, Rimland D. 2007. Hepatitis B reverse seroconversion in HIV-positive patients: Case series and review of the literature. AIDS 21: 771-774.
15. Sheng W, Kao J, Chen P, Huang L, Chang S, Sun H, Hung C, Chen M, Chang S. 2007. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 45: 1221-1229.
16. Vierling JM. 2007. The immunology of hepatitis B. Clin Liver Dis 11: 727-759.